Neurologic Imaging

What Is the Best Initial Imaging for Nonlocalizable, Nonacute Horner Syndrome in Adults?

·
What Is the Best Initial Imaging for Nonlocalizable, Nonacute Horner Syndrome in Adults?

A 58-year-old man presents to your outpatient clinic with a three-week history of a “droopy” left eyelid and a noticeably smaller pupil on that side. He denies any pain, recent trauma, headache, or other neurological symptoms. Your examination confirms unilateral ptosis and miosis, consistent with Horner syndrome. With no clear localizing signs pointing to the brain, spinal cord, or chest, you are faced with a diagnostic challenge: how do you image the entire, lengthy oculosympathetic pathway to find the cause? This article provides a clinical workflow for this specific scenario, guiding you through the American College of Radiology (ACR) recommendations. For an adult with nonacute, nonlocalizable Horner syndrome, the ACR has determined that CTA head and neck with IV contrast is Usually Appropriate as the initial imaging study.

## Who Fits This Clinical Scenario?

This guidance applies specifically to an adult patient presenting with Horner syndrome (the classic triad of ptosis, miosis, and anhidrosis, though anhidrosis can be subtle or absent) that meets three key criteria:

1. Nonacute Onset: The symptoms have developed gradually over days to weeks, without a sudden, dramatic start.
2. Nonlocalizable: The history and physical examination do not point to a specific location of the lesion. There are no other cranial nerve palsies, no signs of a stroke (hemiparesis, aphasia), and no symptoms of spinal cord compression (myelopathy, radiculopathy).
3. No Other Specified Cause: There is no history of recent trauma, neck surgery, or other obvious precipitating event.

It is crucial to distinguish this presentation from similar but distinct clinical scenarios that require a different imaging approach. This workflow does not apply if the patient has:

  • Acute onset with recent trauma: This presentation raises high suspicion for carotid or vertebral artery dissection and follows a different ACR variant.
  • Localizing brain or cranial nerve signs: If the Horner syndrome is accompanied by hoarseness, dysphagia, or other cranial neuropathies (e.g., IX, X, XI), the lesion is likely at the skull base, and the imaging workup is more focused.
  • Localizing spinal cord signs: If the patient also presents with arm weakness, sensory loss in a dermatomal pattern, or signs of myelopathy, the workup should focus on the spinal cord.

Correctly categorizing the patient’s presentation ensures the highest-yield initial study is ordered.

## What Diagnoses Are You Working Up in This Scenario?

Horner syndrome results from a disruption of the three-neuron oculosympathetic pathway, which extends from the hypothalamus down through the brainstem and spinal cord, up over the lung apex, and along the carotid artery to the eye. A nonlocalizable presentation means a lesion could exist anywhere along this extensive route. The initial imaging aims to survey this entire path for the most common and most dangerous causes.

The primary differential diagnoses in this scenario include:

Apical Lung Malignancy (Pancoast Tumor): A tumor at the superior sulcus of the lung is a classic cause of Horner syndrome. It can directly invade or compress the preganglionic (second-order) sympathetic fibers as they exit the thorax. In a patient with a smoking history, this is a primary concern.

Carotid Artery Dissection: While often associated with acute, painful Horner syndrome, dissection can also present subacutely or without pain. A mural hematoma in the internal carotid artery can compress the adjacent postganglionic (third-order) sympathetic plexus. Missing this diagnosis can lead to thromboembolic stroke, making it a critical entity to exclude.

Neck or Mediastinal Mass: Other masses, such as thyroid carcinoma, neurogenic tumors (e.g., schwannoma), or enlarged lymph nodes in the neck or superior mediastinum, can compress the sympathetic chain.

Skull Base Pathology: Less commonly, slow-growing tumors or inflammatory processes at the skull base or in the cavernous sinus can disrupt the third-order sympathetic neurons.

The goal of the initial imaging is to provide a comprehensive survey capable of identifying these varied vascular, neoplastic, and structural causes.

## Why Is CTA Head and Neck with IV Contrast the Recommended Study?

For an adult with nonacute, nonlocalizable Horner syndrome, the ACR designates CTA head and neck with IV contrast as Usually Appropriate. This recommendation is based on the modality’s ability to rapidly and accurately assess the full anatomical course of the sympathetic pathway for the most critical pathologies.

The rationale for choosing CTA includes:

  • Comprehensive Vascular and Soft Tissue Assessment: CTA provides excellent visualization of the major arteries from the aortic arch through the circle of Willis, making it highly sensitive for detecting carotid artery dissection, aneurysms, or significant atherosclerotic disease. The use of intravenous contrast also opacifies and delineates soft tissue masses in the neck, mediastinum, and lung apex, allowing for the detection of a Pancoast tumor or other compressive lesion in a single scan.
  • Speed and Accessibility: CT angiography is widely available, rapidly acquired, and less susceptible to motion artifact compared to MRI, which is a practical advantage in many clinical settings.

Why are other studies rated lower for this specific scenario?

  • MRA head and neck without and with IV contrast is rated Usually not appropriate. While MRA avoids ionizing radiation, it can be less robust for identifying subtle, non-occlusive carotid dissections compared to CTA. Furthermore, standard MRA protocols may not include the chest apex with the same diagnostic quality as a dedicated CTA, potentially missing a small Pancoast tumor.
  • MRI of the cervical and thoracic spine is also rated Usually not appropriate as the initial study. While excellent for evaluating intrinsic spinal cord pathology, it does not adequately assess the carotid arteries, skull base, or lung apices, providing an incomplete picture for a nonlocalizable workup. It becomes a valuable second-line test if the CTA is negative and suspicion for a central or preganglionic spinal cause remains high.

The radiation dose for a CTA head and neck is moderate, with a relative radiation level of ☢☢☢ (1-10 mSv). This exposure is considered justified given the need to exclude life-threatening conditions like malignancy and arterial dissection. When ordering, be sure to specify “CTA head and neck” or “CTA from arch to vertex” to ensure the protocol covers the entire relevant anatomy.

Once you’ve decided on CTA head and neck with IV contrast, our protocol guide covers the technique, contrast, and reading principles: CTA Head and Neck (Carotid + COW).

## What’s Next After CTA Head and Neck with IV Contrast? Downstream Workflow

The results of the initial CTA will guide your subsequent management. The workflow typically branches into one of three paths:

  • Positive and Definitive Finding: If the CTA identifies a clear cause, such as a Pancoast tumor, carotid artery dissection, or large aneurysm, the next step is referral to the appropriate specialty. A lung mass would prompt a consultation with pulmonology or oncology for biopsy. A carotid dissection requires immediate consultation with neurology and/or vascular surgery for anticoagulation or other intervention.
  • Negative Finding: A negative CTA is reassuring, as it effectively rules out the most urgent causes like dissection and large masses. However, Horner syndrome is still unexplained. At this point, the workup may proceed to pharmacologic testing (e.g., apraclonidine or cocaine eye drops) to confirm the diagnosis and help localize the lesion to a pre- or postganglionic site. If clinical suspicion for a central (first-order neuron) or subtle preganglionic (second-order neuron) cause remains, a follow-up MRI/MRA of the brain and neck or a dedicated MRI of the brachial plexus/thoracic inlet may be considered.
  • Indeterminate Finding: Occasionally, the CTA may reveal an ambiguous finding, such as subtle vessel wall irregularity or a nonspecific soft tissue prominence. In these cases, correlation with a different imaging modality, often a contrast-enhanced MRI of the specific area of concern, is the logical next step to better characterize the tissue and confirm or exclude pathology.

## Pitfalls to Avoid (and When to Get Help)

When working up nonlocalizable Horner syndrome, be mindful of these common pitfalls:

  • Ordering a Non-Contrast Study: A CT of the neck or head without IV contrast is insufficient for this indication, as it will fail to detect critical vascular pathology.
  • Incomplete Anatomical Coverage: Ensure your imaging order covers the full pathway from the superior mediastinum to the intracranial circulation. Ordering only a “CTA Neck” might truncate the scan at the lung apices or the skull base.
  • Dismissing a “Normal” Scan: A negative CTA does not mean the patient does not have Horner syndrome; it means the most common life-threatening structural causes have been reasonably excluded. The workup is not necessarily over.
  • Ignoring Subtle Symptoms: Do not disregard subtle associated symptoms. Re-question the patient about neck pain, arm pain/weakness, or changes in voice, as these may help localize the lesion and change the imaging plan.

If the CTA is negative but the clinical picture is concerning or evolving, consultation with a neurologist is the appropriate next step to guide further diagnostic testing.

## Related ACR Topics and Tools

For a comprehensive overview of imaging for all clinical variants of Horner syndrome, or to explore the technical details of the recommended study, the following resources are available:

Frequently Asked Questions

Why is CTA preferred over MRA if the patient is young and I want to avoid radiation?

While minimizing radiation is always a goal, the ACR recommends CTA as ‘Usually Appropriate’ and MRA as ‘Usually not appropriate’ for this specific scenario because CTA is generally faster, more widely available, and considered more robust for detecting subtle carotid artery dissections and small apical lung masses in a single examination. The clinical urgency of ruling out these conditions often outweighs the moderate radiation dose.

If the CTA is negative, is the workup for Horner syndrome complete?

No. A negative CTA is a crucial step that rules out many of the most dangerous causes like dissection, aneurysm, and large tumors. However, it does not exclude all possible causes. The next steps often involve pharmacologic eye drop testing to confirm and localize the sympathetic lesion, followed by more targeted imaging like an MRI of the brain or brachial plexus if indicated.

What if my patient has a contraindication to iodinated contrast, like a severe allergy or poor renal function?

In cases of a strong contraindication to CT contrast, an MRA head and neck without and with gadolinium-based contrast would become the next best alternative, despite its lower ACR rating for this scenario. It is crucial to weigh the risks of the contrast agent against the diagnostic benefit. Consultation with radiology can help determine the safest and most effective imaging plan.

Does this guidance apply if the Horner syndrome is painful?

Not necessarily. The presence of pain, particularly acute neck or head pain, significantly increases the suspicion for carotid artery dissection. While CTA is still the correct study, the clinical scenario is different and falls under a more urgent ACR variant. This article specifically addresses nonacute, nonlocalizable presentations.

Should I order a chest X-ray first to look for a Pancoast tumor?

A chest X-ray may identify a large, obvious apical mass, but it has low sensitivity for small tumors and provides no information about the vascular structures in the neck and head. The recommended CTA head and neck protocol includes the lung apices and is far more sensitive for detecting both the primary tumor and any potential vascular involvement, making it a much more comprehensive and efficient first test.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026